PDCD1 and non-small cell lung carcinoma: Taking pharmaceutical treatment of PD-1 as an example, clinical data showed that only about 20% PD-L1–positive NSCLC (which accounts for 85% of all lung cancers) patients respond objectively to ICT (16, 17).